Hyderabad, April 12 : Bharat Serums and Vaccines Limited (BSV) on Tuesday announced to invest INR 200 crore in the state-of-the art injectable and vaccine manufacturing facility at Genome Valley here. This was announced by BSV Managing Director and Chief Executive Officer Sanjiv Navangul during a meeting with Telangana Minister for Industries K T Rama Rao. The facility will produce women’s health products, rabies vaccines, immunoglobulins, hormones, among others. BSV, one of the fastest growing bio-pharmaceutical companies in India , has used its scientific resources to develop a range of biological, biotech and pharmaceutical products. Today, they influence patient outcomes in the therapeutic areas of Women’s health and Critical Care and IUI-IVF and have become a partner of choice. BSV, which is amongst the top 10 Biotech companies in the country, has in its portfolio over 145 brands. The Company has over 1000 employees selling its products across the country with their brands being marketed all over India and exported to over 70 countries across the world. During the meeting, the Minister said that “entry of Bharat Serums Vaccines further highlights the strength of the life sciences sector in Telangana State”. The Telangana government will extend all the support required by Bharat Serums and will also partner with it in areas like improving women’s health. Genome Valley is India’s first organized cluster for Life Sciences R&D and Clean Manufacturing activities, with world-class infrastructure facilities in the form of Industrial / Knowledge Parks, Special Economic Zones (SEZs), Multi-tenanted dry and wet laboratories and incubation facilities. It is home to more than 200 companies with a scientific workforce of about 15,000 professionals including presence of the marquee global names like Novartis, GlaxoSmithKline, Ferring Pharma, Chemo, DuPont, Ashland, ted States Pharmacopeia, Lonza amongst many others. The cluster is also home to three of India’s largest vaccine manufacturers, namely Bharat Biotech, Biological E and Indian Immunologicals. Telangana Principal Secretary of Industries & Commerce Jayesh Ranjan and Telangana State Life Sciences and Pharma Director Shakthi Nagappan also attended the meeting. KNR CS1702